COMPARISN of EMPAGLIFLOZIN & DAPAGLIFLOZIN FOR ANTIDIABETIC.pptx

Comparion of Empagliflozin and Dapagliflozin in diabetic treatment for Heart disease patient

1. EMPAGLIFLOZIN & DAPAGLIFLOZIN

2. PREVIEW DIABETIC: Prevalence Market Size Diabetic GUIDELINE SGLT2-inhibitor MARKET VIEW EMPA & DAPA STP

3. Empagliflozin and dapagliflozin are both medications in a class called SGLT-2 inhibitors used to treat type 2 diabetes. Here are some key points about each: Empagliflozin: Brand name: Jardiance Approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease Can help lower blood sugar levels by causing the kidneys to remove sugar through urine Side effects can include urinary tract infections, genital yeast infections, and low blood pressure

4. Dapagliflozin: Brand name: Farxiga Used to improve glycemic control in adults with type 2 diabetes Can also lead to weight loss and reduce blood pressure Common side effects include urinary tract infections and genital yeast infections Both medications can be effective in managing blood sugar levels in individuals with type 2 diabetes, but the choice between the two often depends on factors such as individual health needs, side effect profiles, and personal preferences. It is important to discuss with a healthcare provider to determine the most suitable option for each individual.

5. Brand Names : Empagliflozin is sold under the brand name Jardiance, while dapagliflozin is sold under the brand name Farxiga . Effectiveness : Both medications have been shown to effectively lower blood sugar levels in people with type 2 diabetes. However, some studies suggest that empagliflozin may have additional cardiovascular benefits beyond just lowering blood sugar. Dosage : The recommended dosage of empagliflozin and dapagliflozin can vary. It's important to follow the prescribed dosage provided by your healthcare provider. Side Effects : Common side effects of both medications may include urinary tract infections, genital yeast infections, and increased urination. However, individual experiences with side effects can vary. Cost : The cost of these medications can vary depending on various factors such as insurance coverage, pharmacy discounts, and whether generic options are available. It's important to consult with your healthcare provider to determine which medication may be more suitable for your specific health needs and medical history.

6. EMPAGLIFlOZIN -JARDIANCE-BI Approve EMA Apr 2014, FDA Aug 2014 EXP Date: Aug 2028 Aug 2014 approve for DM type 2, Aug 2016 approved untuk mengurangi kematian krn Jantung pd pasien Benefit: In overt atherosclerotic CVD and/or heart failure patients with suboptimal glycemic control despite metformin and lifestyle modification  menekan ROS pada mitokondria sel pada pasien Atrial Fibrilasi Nephropathy (urine albumin-to-creatinine >300 mg/g) As a third-line agent in case of suboptimal glycemic control despite using two oral drugs, or metformin and insulin therapy As a second-line agent in cases of suboptimal glycemic control for patients with metformin who cannot take insulin and weight gain and hypoglycemia is a significant issue.  https://pharsight.greyb.com/drug/jardiance-patent-expiration

7. Liraglutide, empagliflozin, and dapagliflozin are all medications used to manage type 2 diabetes mellitus, but they belong to different classes of drugs and work in distinct ways: Liraglutide : Class : GLP-1 receptor agonist (incretin mimetic) Mechanism of Action : Stimulates the GLP-1 receptor, which increases insulin secretion in response to meals, reduces glucagon secretion (which lowers blood glucose levels), and slows gastric emptying. It also promotes weight loss. Administration : Typically injected subcutaneously once daily. Empagliflozin : Class : SGLT2 inhibitor Mechanism of Action : Blocks the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, which reduces renal glucose reabsorption. This leads to increased glucose excretion in urine and lowers blood glucose levels. It also has cardiovascular benefits. Administration : Taken orally once daily. Dapagliflozin : Class : SGLT2 inhibitor (similar to empagliflozin) Mechanism of Action : Like empagliflozin, dapagliflozin inhibits SGLT2, thereby reducing renal glucose reabsorption and increasing urinary glucose excretion. Administration : Also taken orally once daily. Key Comparisons : Mechanism : Liraglutide works by mimicking the action of GLP-1, whereas empagliflozin and dapagliflozin inhibit SGLT2 to enhance glucose excretion. Weight Effects : Liraglutide often leads to weight loss due to its effects on satiety and gastric emptying, whereas SGLT2 inhibitors like empagliflozin and dapagliflozin can lead to modest weight loss due to calorie loss through increased urinary glucose excretion. Cardiovascular Benefits : Both empagliflozin and dapagliflozin have shown significant cardiovascular benefits in clinical trials, whereas liraglutide has shown benefits primarily in terms of weight loss and some cardiovascular risk factors. Side Effects : Each medication has its own set of potential side effects. For example, GLP-1 agonists like liraglutide may cause gastrointestinal issues, while SGLT2 inhibitors like empagliflozin and dapagliflozin are associated with an increased risk of urinary tract infections and genital mycotic infections. Administration : Liraglutide is administered via injection, while empagliflozin and dapagliflozin are taken orally. Clinical Considerations : Individualization : The choice between these medications often depends on individual patient factors, including comorbidities, cardiovascular risk profile, renal function, preferences for oral vs. injectable medications, and potential side effects. Combination Therapy : They can be used alone or in combination with other diabetes medications (such as metformin or insulin) to achieve optimal blood glucose control. In summary, while all three medications are used in the treatment of type 2 diabetes, they differ in their mechanisms of action, administration routes, potential side effects, and additional cardiovascular benefits. The selection of one over the other often depends on individual patient characteristics and treatment goals.